优贺丁治疗E抗原阳性慢性乙型肝炎的临床观察

The Therapy with Adefovir Dipivoxil for HBeAg-positive Chronic Hepatitis B

目的观察国产阿德福韦酯(优贺丁)对E抗原阳性的慢性乙型肝炎的临床疗效及安全性。方法入选患者口服阿德福韦酯10mg/d,观察疗程48周。治疗前、治疗12周、24周、48周时检测肝功、肾功、HBV-DNA病毒载量。结果本组25例治疗48周,病毒阴转率56%(14/25),ALT复常率76%(19/25)。结论国产阿德福韦(优贺丁)治疗E抗原阳性慢性乙型肝炎患者,在病毒学及生化学方面取得良好应答,安全性较好。

Objective To verify the efficacy and safety of adeforvir dipivoxil in the treatment of HBeAg- positive chronic hepatitis B （CHB）. Methods A total of 25 HBeAg-positive patients with CHB were treated with adeforvir dipivoxil （10mg/d） for 48 weeks. We mostly observed the change of the level of ALT and HBV DNA at the end ofl2th, 24th and 48th week. Results After 48 wk of treatment, the viral response rates were 56%（14/25）, and the ALT/AST normalization rates were 76%（19/25）. Conclusion Adeforvir dipivoxil has obvious effect on viral and biochemical responses in HBeAgpositive chronic hepatitis B, and it is effective and safe in the treatment of CHB.